MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Georgoussi, Z.
Right arrow Articles by Milligan, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Georgoussi, Z.
Right arrow Articles by Milligan, G.

Direct measurements of in situ interactions of rat brain opioid receptors with the guanine nucleotide-binding protein Go

Z Georgoussi, C Carr and G Milligan

Institute of Biology, National Center for Scientific Research, Demokritos, Athens, Greece.

The interactions of rat brain cortical opioid receptors with the guanine nucleotide-binding protein (G protein) Go were probed in membranes by examining the ability of selective antipeptide anti-G protein antisera to disrupt receptor-G protein interactions. This was measured both by antibody-induced alterations in the characteristics of agonist binding to mu and delta receptor binding sites and by antibody attenuation of opioid stimulation of high affinity GTPase activity. Antisera to the amino-terminal 16 amino acids (ON1), amino acids 22-35 (IM1), and the carboxyl-terminal decapeptide (OC2) of forms of Go alpha were able to selectively immunoprecipitate Go from rat cortical membranes. Both antisera OC2 and ON1 were able to immunoprecipitate Go alpha quantitatively. Preincubation of rat cortical membranes with an IgG fraction isolated from antiserum OC2 was able to produce a marked reduction in the ability of the synthetic enkephalin [D-Ala2,D-Leu5] enkephalin (DADLE) (which interacts with delta and mu but not significantly with kappa receptors) to displace specific binding of [3H] diprenorphine (which binds to all of these sites), demonstrating a clear interaction of the mu and delta receptors with one or more variants of Go. An IgG fraction from antiserum ON1 was able to mimic this effect, suggesting that the amino-terminal region of G protein alpha subunits also plays a role in receptor-G protein interactions. In contrast, an IgG fraction from antiserum IM1 was unable to alter the characteristics of DADLE displacement of [3H] diprenorphine binding. Similarly, an antiserum (SG1) directed against the carboxyl-terminal decapeptide common to the alpha subunits of Gi1 and Gi2 was unable to reduce the affinity of DADLE binding to opioid receptors. Use of antiserum OC2 in experiments that allowed pharmacological examination of only the mu-opioid receptor provided independent evidence for the interaction of this receptor site with Go.

Volume 44, Issue 1, pp. 62-69, 07/01/1993
Copyright © 1993 by American Society for Pharmacology and Experimental Therapeutics




This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
E. Morou and Z. Georgoussi
Expression of the Third Intracellular Loop of the {delta}-Opioid Receptor Inhibits Signaling by Opioid Receptors and Other G Protein-Coupled Receptors
J. Pharmacol. Exp. Ther., December 1, 2005; 315(3): 1368 - 1379.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. Waldhoer, A. Wise, G. Milligan, M. Freissmuth, and C. Nanoff
Kinetics of Ternary Complex Formation with Fusion Proteins Composed of the A1-Adenosine Receptor and G Protein alpha -Subunits
J. Biol. Chem., October 22, 1999; 274(43): 30571 - 30579.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1993 by the American Society for Pharmacology and Experimental Therapeutics